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Porcine circovirus type 2 (PCV2) is one of the economically most important pathogens for swine production
worldwide. Vaccination is a powerful tool to control porcine circovirus diseases (PCVD). However, it is not fully
understood how PCV2 vaccination interacts with the porcine immune system. Especially knowledge on the cellular
immune response against PCV2 is sparse. In this study we analysed antigen-specific T cell responses against PCV2 in
a controlled vaccination and infection experiment. We focused on the ability of CD4+ T cells to produce cytokines
using multicolour flow cytometry (FCM). Vaccination with a PCV2 subunit vaccine (Ingelvac CircoFLEXW) induced
PCV2-specific antibodies only in five out of 12 animals. Conversely, vaccine-antigen specific CD4+ T cells which
simultaneously produced IFN-γ and TNF-α and had a phenotype of central and effector memory T cells were
detected in all vaccinated piglets. After challenge, seroconversion occurred earlier in vaccinated and infected pigs
compared to the non-vaccinated, infected group. Vaccinated pigs were fully protected against viremia after
subsequent challenge. Therefore, our data suggests that the induction of IFN-γ/TNF-α co-producing T cells by PCV2
vaccination may serve as a potential correlate of protection for this type of vaccine.Introduction
Since the first description of porcine circovirus by Tischer
et al. in 1982 [1], porcine circovirus type 2 (PCV2) has be-
come one of the most important pathogens affecting the
swine industry worldwide [2]. PCV2 is the causative agent
of a number of disease syndromes summarized as porcine
circovirus diseases (PCVD) among which postweaning
multisystemic wasting syndrome (PMWS) is the econo-
mically most important [3,4]. Single PCV2 infection rarely
results in clinical disease [5]. In the majority of cases pigs
are subclinically infected [4]. However, coinfections with
porcine reproductive and respiratory syndrome virus
(PRRSV), porcine parvovirus (PPV) or Mycoplasma hyop-
neumoniae (M. hyo) are common and lead to more severe
clinical symptoms [6,7].
In 2006 the first commercial PCV2 vaccines were intro-
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unless otherwise stated.encoded capsid proteins were found to be immunogenic
which made them suitable for vaccine development [9,10].
Indeed, two of four commercial PCV2 vaccines are based
on recombinant ORF2 capsid proteins. Currently, PCV2
vaccination is widely used to combat PCVD. Different
vaccines are commercially available and have successfully
contributed to a decrease in mortality and an increase
in growth parameters [11], probably via a reduction of
PMWS severity [12]. Therefore, they are considered as
an efficient tool to control PMWS [13].
The majority of domestic pigs are seropositive for
PCV2-specific antibodies [12,14]. Of note, viremia is
frequently detected in seropositive pigs. This led to the
assumption that antibodies against PCV2 are not fully
protective [15,16]. Furthermore, previous studies indicated
that the analysis of antibody titres is often not sufficient to
evaluate a protective immune response against PCV2 [17].
Other findings underline the importance of neutralizing
antibodies. PMWS-affected pigs have lower titres of neu-
tralizing antibodies than subclinically infected animals
[18] and high titres of neutralizing antibodies are inverselyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mune responses for protection against PCV2 is less well
studied. It was shown that cellular immune responses are
directed against capsid proteins as well as against the
ORF1 encoded replicase protein [20]. Apparently, CD4+
and CD8+ T cells are involved in this response [21]. In
addition, one study showed that virus clearance coincides
with the appearance of PCV2-specific IFN-γ secreting
cells (SC) [22].
The aim of the present study was to elucidate the
role of antigen-specific cellular immune responses after
PCV2 vaccination with a commercially available PCV2
subunit vaccine (Ingelvac CircoFLEXW). Since the ana-
lysis of PCV2-specific antibodies is not sufficient to pre-
dict protection against PCVD, antigen-specific cellular
immune responses might play an important role. During
a controlled vaccination and infection experiment we
monitored clinical signs and analysed PCV2 viral load in
serum samples by quantitative polymerase chain reac-
tion (qPCR). Additionally, we investigated the humoral
immune response by determination of PCV2-specific
antibodies using a commercially available ELISA kit. The
main interest was the determination of antigen-specific
T cell responses. We analysed in detail the ability of
CD4+ T cells to produce IFN-γ and TNF-α by intracellu-
lar cytokine staining using multicolour flow cytometry
(FCM). Our results provide first indications that the in-
duction of IFN-γ/TNF-α co-producing CD4+ T cells by
PCV2 vaccination is associated with a reduction of
viremia and therefore, might contribute to a protection
against PCVD.
Materials and methods
Animals and study design
24 crossbred three week-old piglets (Large White X
Landrace X Pietrain) were obtained from a conventional
farm in Lower Austria and housed in the isolation
unit of the Vetmeduni Vienna. On arrival, the piglets
were weighed and divided into two groups according to
their bodyweight. Half of the animals were vaccinated
with a PCV2 subunit vaccine (Ingelvac CircoFLEXW,













Figure 1 Time schedule of the animal experiment. Piglets were weighe
experiment. PCV2 vaccination was performed on study day 0. Piglets were
samples were taken twice before challenge (−4, 24 dpv) and 5 times there
isolation of PBMCs were taken on the day of vaccination, on day 24 post vaccording to the manufacturer’s instructions on study
day 0. Twenty-four days post vaccination (dpv) half of
the vaccinated and non-vaccinated pigs were intranasally
infected with a PCV2a field isolate (93965, origin
Poland, provided by Boehringer Ingelheim). One mL of
a virus suspension containing 105 TCID50 of PCV2/mL
was administered into each nostril. During the entire ex-
periment the pigs were kept under ordinary husbandry
conditions. Infected and non-infected animals were kept
in separate compartments. Clinical signs were monitored
daily. Blood samples were taken by puncture of the V.
cava cranialis or V. jugularis as indicated in the timeline
(Figure 1). Sera were obtained for the detection of
PCV2-specific antibodies and for the determination of
PCV2 viremia. Whole blood samples were taken to iso-
late PBMCs at 0 dpv, 24 dpv, 42 dpv and 56 dpv. For
calculation of the average daily weight gain, piglets
were weighed three times (Figure 1). The animal experi-
ment was approved by the institutional ethics committee,
the Advisory Committee for Animal Experiments (§12
of Law for Animal Experiments, Tierversuchsgesetz –
TVG) and the Federal Ministry for Science and Research
(reference number BMWF 68.205/0109-II/3b/2011).
Determination of viral load
Viremia was analysed by qPCR specific for ORF1 PCV2
DNA. The protocol for the qPCR was established at
the University Clinic for Swine in cooperation with Dr
Ingrid Huber (Bavarian Health and Food Safety Authority,
Oberschleißheim, Germany). Both PCV2 primers and the
probe attached within ORF1. Forward primer 5′-GGT
ACT CCT CAA CTG CTG TCC-3′, reverse primer 5′-
GGG AAA GGG TGA CGA ACT GG-3′ and the probe
5′-ACA GAA CAA TCC ACG GAG GAA GGG-3′ were
purchased from TIB MOLBIOL (TIB MOLBIOL GmbH,
Berlin, Germany). 6-carboxyfluorescein was used as fluo-
rochrome and tetramethylrhodamine as quencher (TIB
MOLBIOL GmbH). To create a standard curve for quan-
tification of PCV2 DNA in the samples, a PCV2 PCR
product was cloned into the PCR Cloning Vector pSC-A-
amp/kan according to the manufacturer’s instructions
(StrataCloneTM PCR Cloning Kit, Stratagene, Amsterdam,56 dpv 
Euthanasia







d after arrival and subsequently two more times in the course of the
inoculated with a PCV2a isolate 24 days post vaccination (dpv). Serum
after (28, 35, 42, 49, 56 dpv). Heparinized blood samples for the
accination, 42 dpv and at the end of the study (56 dpv).
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produced by PCV2-specific PCR. After accumulation in
Escherichia coli the obtained plasmid DNA was purified
using Plasmid Midi Kit (Qiagen, Hilden, Germany) as
recommended by the manufacturer. Different dilutions
(102-109 copies/mL) of the purified plasmid DNA were
used to establish a standard curve. As internal PCR
control system a 125 bp fragment of Nicotiana tabacum
(provided by I. Huber, Bavarian Health and Food Safety
Authority) was used to avoid false negative results due to
inhibitory effects of the sample matrix. Viral DNA was
extracted from serum samples using High Pure PCR
Template Preparation Kit (Roche, Mannheim, Germany)
as recommended by the manufacturer. Thereafter DNA
samples were diluted 1:10 with diethylpyrocarbonate-
treated water (DEPC-treated water, Thermo Fisher
Scientific, Waltham, MA, USA). A mastermix was pre-
pared which contained Brilliant II QPCR MasterMix
(Stratagene), PCV2 primers and PCV2 probe (TIB
MOLBIOL GmbH) as well as primers and probe for
the internal PCR control (provided by I. Huber, Bavarian
Health and Food Safety Authority). The internal PCR
control was added and the mastermix was pipetted to
the DNA samples. A known positive serum was used as
positive control. Additionally, a negative control con-
taining DEPC-treated water (Thermo Fisher Scientific)
was included in the qPCR assay. Finally, DNA frag-
ments were amplified using Mx3005P Real Time Cycler
(Stratagene). Thermocycling conditions involved an ini-
tial activation step of 95 °C for 10 min followed by
45 cycles of 95 °C for 15 s and 60 °C for 1 min. The PCR
raw data was analysed using MxPro Software (Stratagene).
The detection limit of the PCR was 25 virus copies/mL
serum. Samples below this detection level were regarded
as negative.
Determination of PCV2-specific antibody titres
Sera were analysed for PCV2-specific antibodies by a
commercially available ELISA kit (INGEZIM Circovirus
IgG/IgM, Ingenasa, Madrid, Spain) according to manu-
facturer’s instructions. The ELISA was performed usingTable 1 Antibodies for FCM staining
Antigen Clone Isotype Fluorochro
CD4 74-12-4 IgG2b Alexa488a
CD8α 76-2-11 IgG2a PE-Cy7b
CD27 b30c7 IgG1 Alexa647c
IFN-γ P2G10 IgG1 PEd
TNF-α MAb11 IgG1 BV605e
aAlexa488: Goat anti-Mouse IgG2b-Alexa488, Life Technologies, Carlsbad, CA, USA.
bPE-Cy7: Goat anti-Mouse IgG2a-PE-Cy7, Southern Biotech, Birmingham, AL, USA.
cAlexa647: Protein Labelling Kit Alexa 647, Life Technologies, Carlsbad, CA, USA.
dPE, BD Biosciences, San Jose, CA, USA.
eBrilliant Violet605, BioLegend, San Diego, CA, USA.an automated ELISA processing system (Dynex DS2W,
Dynex Technologies, Chantilly, VA, USA).
Isolation of peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from heparinized blood samples
by gradient centrifugation using lymphocyte separation
medium (PAA, Pasching, Austria). The isolation proce-
dure was performed as previously described [23]. After
isolation, 3–6 × 107 PBMCs per cryo tube were frozen
in freezing medium (50% RPMI 1640, PAN Biotech,
Aidenbach, Germany, 40% fetal calf serum (FCS), PAA,
10% Dimethylsulfoxide, Sigma, Vienna, Austria) and stored
at −150 °C.
In vitro re-stimulation of PBMCs and intracellular cytokine
staining (ICS)
Defrosted PBMCs were counted and 5 × 105 cells per
well were plated (U-bottomed 96-well microtitreplates,
Greiner Bio One, Frickenhausen, Germany) in 150 μL
culture medium (RPMI 1640, 10% FCS, 100 IU/mL
penicillin, PAA). Cells were cultured at 37 °C and 5%
CO2 for four hours. Subsequently, PBMCs were stimu-
lated with 4 μg/mL baculovirus-expressed capsid pro-
tein (PCV2-ORF2, provided by Boehringer Ingelheim).
Cells cultured in medium only served as negative control.
Stimulation with supernatant of baculovirus infected
cell cultures was performed in separate experiments
and did not show any difference to the medium control.
After overnight incubation, 1 μg/mL Brefeldin A (BD
GolgiPlugTM, BD Biosciences, San Jose, CA, USA) was
added and cells were incubated for another four hours.
Afterwards, 12 wells per stimulation group were pooled
and PBMCs were washed twice using phosphate buffered
saline (PBS, PAN Biotech) containing 3% FCS (PAA). Six-
colour FCM staining was performed in U-bottomed 96-
well microtitreplates (Greiner Bio One). Table 1 provides
information on antibodies used for FCM staining. Prior to
use, all antibodies had been titrated and optimal working
dilutions were determined according to the maximal
staining index. Mastermixes of antibodies were prepared
for each incubation step; incubations were performed forme Labelling strategy Source of primary Ab
Secondary antibody In house
Secondary antibody In house
Directly conjugated In house
Directly conjugated BD Biosciences
Directly conjugated BioLegend
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by two washing steps with 200 μL of FCM buffer (PBS
containing 3% FCS) and centrifugation. The cells were re-
suspended using a plate shaker after each washing step.
Cell surface markers were labelled by monoclonal anti-
bodies (mAbs) against CD4, CD8α and CD27 (see Table 1
for details), followed by incubation with isotype-specific
fluorochrome-labelled secondary antibodies. Fixable Near-
IR Dead Cell Stain Kit (Life Technologies, Carlsbad, CA,
USA) was included in the mastermix of secondary anti-
bodies to discriminate live from dead cells. Mastermixes
for primary antibodies were prepared in PBS containing
3% FCS; secondary antibodies were prepared in PBS only.
After labelling of cell surface markers, cells were fixed and
permeabilized by BD Cytofix/Cytoperm (BD Biosciences)
according to manufacturer’s instructions. Finally, mAbs
against IFN-γ and TNF-α were added. Single stain sam-
ples for each fluorochrome were prepared as compensa-
tion controls.
Flow cytometry analysis
Samples were analysed using a FACSCanto II (BD Biosci-
ences) flow cytometer equipped with three lasers (405,
488 and 633 nm). After measurement of compensation
controls, compensation was calculated by FACSDiva soft-
ware Version 6.1.3 (BD Biosciences). Flow cytometric
data was analysed with the same version of FACSDiva
software.
Statistics and preparation of diagrams
Statistics were calculated using IBM SPSSW Statistics 20
(IBM Corp., Armonk, NY, USA). Data was tested for nor-
mal distribution using Kolmogorov-Smirnov test. Analysis
of variance (ANOVA) was performed to compare the four
study groups. Tukey’s range test was used for post-hoc
analysis. For not normally distributed data Kruskal-Wallis
test and consequently Mann–Whitney tests were exe-
cuted to evaluate differences between the treatment
groups. To analyse differences within one study group,
paired t-tests were conducted for normally distributed
data and Wilcoxon tests were used for not normally
distributed data. Bar charts and scatter diagrams were
created in Excel 2010 (Microsoft, Redmond, WA, USA).
Results
To evaluate the influence of vaccination against PCV2
with the recombinant baculovirus PCV2-ORF2 vaccine
(Ingelvac CircoFLEXW) and subsequent challenge on the
generation of antigen-specific T cells, 24 piglets were
divided into four groups. Six piglets were immunized
intramuscularly with the Ingelvac CircoFLEXW vaccine
and represented the vaccinated group (VA). Another six
piglets were vaccinated and intranasally infected (VI) at
24 dpv with a PCV2a isolate. An additional group of sixanimals was non-vaccinated and infected with the same
virus strain at day 24 and represented the infection
group (IN). Six non-vaccinated and non-infected animals
served as controls (CO). The time course of the experi-
ment is presented in Figure 1.
Clinical signs
On arrival, all piglets included in the study were clinic-
ally healthy. Vaccination did not induce any clinical
signs. Likewise, no signs of disease were detected after
PCV2 inoculation. None of the piglets showed any signs
of PCVD throughout the entire study, despite the fact
that PCV2 DNA could be detected in serum of five out
of six animals in the IN group starting from day 35 (see
below). No significant difference was found in average
daily weight gain before and after PCV2 inoculation be-
tween the four study groups (data not shown).
PCV2 viral load in serum samples
Sera of all animals were investigated by qPCR for ORF1
DNA. No PCV2 nucleic acids were found in the serum
samples taken on study day −4 and 24 dpv, i.e. prior to
infection, and also four days after infection (28 dpv).
The earliest time point for the detection of PCV2 DNA
in the sera was 35 dpv (11 days after infection), and only
one animal in the IN group was positive (Figure 2, IN,
animal #3, IN3). In IN animals viremia could be de-
tected at 42 dpv (18 days after infection) in four out of
six animals. A viral load of > 104 PCV2 copies/mL serum
was found in four of the positive pigs (IN3, IN4, IN5,
IN6). One animal (IN1) had a viral load of >106 PCV2
copies/mL on two consecutive examination time points
(42 dpv, 49 dpv) (Figure 2, IN). Another animal (IN2) did
not show any detectable viremia at all investigated time
points after infection. At 56 dpv (32 days after infection)
no viral DNA could be detected in any sera of the IN
group. All animals in the VI group (Figure 2) stayed
negative for PCV2 DNA during the entire experiment.
Likewise, sera of the CO and VA group remained free
of PCV2 nucleic acids (Figure 2 and summarized in
Figure 3A).
Serology
For a determination of the humoral immune response
after PCV2 vaccination and infection, we analysed serum
samples by a commercial ELISA (INGEZIM Circovirus
IgG/IgM, Ingenasa, Madrid, Spain) which differentiates be-
tween PCV2-specific IgM and IgG antibodies. Results are
displayed in a heat map, indicating the presence of PCV2-
specific IgM and IgG antibodies, or both (Figure 3A).
In addition, OD-values derived from this ELISA are shown
in Figure 3B to allow a semi-quantitative evaluation of the
titres in individual animals.
Figure 2 Viral load in animals of the different treatment groups. Sera were analysed for PCV2 DNA by quantitative PCR specific for ORF1.
Line charts represent levels of virus titres in serum samples of individual animals within the four study groups (CO = control, VA = vaccinated,
IN = infected, VI = vaccinated & infected) at all investigated time points before and after PCV2 infection. The detection level of the qPCR was
25 virus copies/mL serum. Samples below this level were regarded as negative. The arrows indicate PCV2 vaccination on study day 0 (SD0) and
experimental PCV2 infection on day 24 post vaccination, respectively.
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the test potentially discriminates between maternal PCV2-
specific IgG antibodies and PCV2-specific IgM antibodies
produced by the piglet. At the beginning of the expe-
riment at day −4, twelve out of 24 piglets had PCV2-
specific IgG antibodies, which were most likely maternally
derived antibodies (Figures 3A and B). However, at 24 dpv
only two animals were positive for IgG, indicating a de-
cline of maternal antibodies. At this time point (24 dpv),
within vaccinated animals (VA, VI), four were positive for
IgM which most probably were induced by vaccination
and one was positive for IgG. Of note, although titres
remained below the cut-off value, in tendency all vacci-
nated animals showed an increase in OD-values for IgM
from −4 dpv to 24 dpv (Figure 3B, VA, VI). After PCV2
inoculation (day 24), piglets from the vaccinated group
(Figures 3A and B, VI) showed an earlier seroconversion
than piglets from the IN group. Four days after infection
(28 dpv), three out of six VI piglets had PCV2-specific
antibodies. One animal (Figures 3A and B, VI1) showed
IgG and IgM antibodies, whereas two other animals (VI5
and VI6) had IgG only. At 35 dpv four out of six animals
in the VI group had seroconverted; 18 days after infection
(42 dpv) all animals of the VI group showed a detectable
antibody titre, with IgG antibodies being present in five of
out of six animals. Only one animal (VI2) had IgM anti-
bodies which could still be detected seven days later (49
dpv) together with IgG molecules. Another seven days
later (56 dpv) only IgG could be identified in piglet VI2.PCV2-specific antibodies developed later in IN animals
(Figures 3A and B, IN). Four days after infection (28 dpv),
all piglets were negative. Seven days later (35 dpv) two out
of six animals showed PCV2-specific antibodies, IN2 IgG
and IN3 IgM. The IgM antibodies in IN3 coincided with
viremia (Figure 3A, IN, black crosses). Another seven days
later (18 days after infection, 42 dpv) IgM antibodies were
present in three animals, all with a detectable viremia
(IN1, IN3, IN4). One animal with detectable virus DNA
(IN5) had not yet seroconverted and one animal with-
out detectable viral DNA showed seroconversion to IgG
antibodies (IN2). At 49 dpv individual animals of the IN
group had either IgG, IgM or both types of antibodies and
56 dpv all IN animals were seropositive. Unlike VI ani-
mals, which were predominantly IgG positive, antibodies
of both investigated isotypes were found across animals of
the IN group. In contrast to the infected groups (IN, VI),
pigs of the VA and CO group were seronegative at the
three time points at the end of the experiment (42 dpv, 49
dpv, and 56 dpv), with the exception of one VA animal
(Figure 3, VA5). Nevertheless, although titres remained
below the cut-off value, in tendency all VA animals
showed an increase in OD-values for IgG from 35 dpv to
56 dpv (Figure 3B).
Cytokine production of CD4+ T cells and phenotype of
cytokine-producing cells
The main focus of this study was the analysis of PCV2-
specific CD4+ T cell responses in regard to IFN-γ/TNF-α
days post vaccination
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Figure 3 PCV2-specific IgM/IgG antibodies and coincidence with viremia. Serum samples were analysed for PCV2-specific antibodies by a
commercially available ELISA kit (INGEZIM Circovirus IgG/IgM, Ingenasa, Madrid, Spain). A) The heatmap shows the detection of PCV2-specific IgM
and IgG antibodies for all animals of the different study groups (CO = control, VA = vaccinated, IN = infected, VI = vaccinated & infected). Light grey
fields represent samples positive for IgG. Dark grey fields indicate the detection of IgM antibodies. Black fields illustrate samples containing both
IgM and IgG antibodies. PCV2 infection was performed 24 days post vaccination. Corresponding days post infection are indicated at the bottom
of the table. Occurrence of PCV2 DNA in individual samples is marked by X. X indicates serum samples with < 104 PCV2 copies/mL, XX stands
for > 104 PCV2 copies/mL. B) Raw data of the INGEZIM Circovirus IgG/IgM ELISA is depicted. OD-values, measured at 450 nm, of IgM (left) and IgG
antibodies (right) for individual animals and all sampling points are shown. The red lines indicate the cut-off OD = 1.108 for IgM and OD = 0.821
for IgG, respectively.
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were re-stimulated with the vaccine antigen (PCV2-
ORF2) in vitro and analysed by multicolour FCM. Cells
cultured in medium alone served as controls. In order
to identify rare subsets of cytokine-producing T cells, at
least 8 × 105 lymphocytes per sample, identified by light
scatter properties, were acquired during FCM analyses.
Total CD4+ T cells were gated (Figure 4A) and analysedfor IFN-γ and TNF-α production. To evaluate the me-
mory phenotype of cytokine-producing T cells we further
analysed the expression of the surface markers CD8α and
CD27. The gating strategy and the cytokine analysis are
displayed from representative experiments with PBMCs
isolated from a control (CO, left) and a vaccinated (VA,
right) animal in Figure 4A. Hardly any IFN-γ and IFN-γ/
TNF-α co-producing T cells were detected in pigs belonging
Figure 4 Frequency of PCV2-ORF2-specific cytokine-producing CD4+ T cells. A) Porcine PBMCs were stimulated with PCV2-ORF2 over night
or were cultured in medium as negative control. CD4+ T cells were gated and analysed for production of IFN-γ and TNF-α by intracellular cytokine
staining (top panel). Cytokine-producing CD4+ T cell subsets were further sub-gated for the analysis of CD8α and CD27 expression (bottom panel).
Red dots indicate cytokine-producing CD4+ T cells; grey dots represent total CD4+ T cells. FCM data is shown for one representative animal of the
control (CO) and vaccinated group (VA) at 24 dpv. B) Stacked bar charts indicate percentages of cytokine-producing CD4+ T cells within total
CD4+ T cells from individual animals of the treatment groups (CO = control, VA = vaccinated, IN = infected, VI = vaccinated & infected) prior to
infection (24 dpv) and at the end of the study (56 dpv). Hatched bars represent percentages of IFN-γ single-producing CD4+ T cells and filled bars
illustrate percentages of IFN-γ/TNF-α co-producing CD4+ T cells within total CD4+ T cells.
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response to PCV2-ORF2 was also found in CO ani-
mals. These TNF-α single-producing T cells from CO
animals were CD4+ and mostly had a naïve phenotype
(CD8α−), indicating that this subpopulation does not
represent PCV2-specific memory cells. Therefore, TNF-αsingle-producing T cells were excluded from further ana-
lyses. In contrast, in the vaccinated groups (VA, VI) IFN-γ
single-producing as well as IFN-γ/TNF-α co-producing T
cells were induced after vaccination. These cells were
mainly CD8α+ and therefore, considered as antigen expe-
rienced. CD27+ central memory T cells (TCM) and CD27
−
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lation of cytokine-producing T cells (Figure 4A).
Percentages of CD4+ IFN-γ single and IFN-γ/TNF-α
co-producing T cells at two investigated time points,
prior to challenge (24 dpv) and at the end of the study
(56 dpv), for the individual animals within respective
groups are shown in Figure 4B. Moreover, the mean
values of these two subpopulations for each treatment
group were calculated and subjected to statistical ana-
lyses (Additional file 1). Background levels of about 0.02%
IFN-γ single-producing cells within total CD4+ T cells
were identified in PBMCs isolated from CO animals at 24
dpv and at the end of the study (56 dpv) and the frequen-
cies of IFN-γ/TNF-α co-producing T cells were even lower
(≤0.014%). Cytokine production prior to vaccination was
tested for three animals belonging to either the VI or
the VA group. At 0 dpv CD4+ T cells of all animals showed
minimal IFN-γ/TNF-α production (IFN-γ+TNF-α− ≤
0.014%, IFN-γ+TNF-α+ ≤ 0.0098%; Additional file 2). Also,
cytokine production in samples incubated with cell culture
medium only was close to zero for all animals and time
points (data not shown).
Compared to the CO group the frequency of IFN-γ
producing T cells isolated from animals of the VA group
was higher at 24 dpv. By this time, all animals of the VA
group had higher levels of IFN-γ/TNF-α co-producing T
cells than the controls (p = 0.044). Animal VA6 showed
the most prominent response to vaccination, especially
regarding the development of double cytokine-producing
T cells. The frequency of IFN-γ single as well as IFN-γ/
TNF-α co-producing T cells declined in all VA animals
(p = 0.004 for IFN-γ and p = 0.028 for IFN-γ/TNF-α co-
producing T cells, respectively) towards the end of the
study (56 dpv).Figure 5 Kinetics of PCV2-specific cytokine-producing CD4+ T cells fo
(not vaccinated, IN-group) before infection and 18 or 32 days post infectio
described before and analysed for IFN-γ and TNF-α production. Stacked ba
individual animals. Hatched bars represent percentages of IFN-γ single-prod
co-producing CD4+ T cells within total CD4+ T cells.Before challenge, the IN pigs had similar low frequen-
cies of IFN-γ+ and IFN-γ+TNF-α+ T cells as animals from
the CO group. After experimental PCV2 infection, we ob-
served a strong increase of IFN-γ single-producing T cells
in this group. IN4 had the strongest response to PCV2 in-
fection with a 15-fold enhancement of IFN-γ+CD4+ T cells
by the end of the study. Similar results were obtained for
IFN-γ/TNF-α co-producing T cells (p = 0.046). We found
a strong increase of double cytokine-producing T cells
after PCV2 infection in five IN pigs, among which IN4
was outstanding (0.1996%). IN2 had low levels (0.03%) of
double cytokine-producing T cells before challenge which
did not further increase after PCV2 infection.
Similar to VA animals, VI pigs had elevated frequen-
cies of IFN-γ producing CD4+ T cells compared to their
non-vaccinated counterparts at 24 dpv. Furthermore, a
clear induction of bi-functional T cells in response to
vaccination was detected in all VI animals 24 dpv. In
contrast to IN pigs, no further increase of single or double
cytokine-producing CD4+ T cells was observed after
PCV2 infection. Instead, the frequency of cytokine-
producing T cells slightly declined towards the end of
the study.
Results from the VI group had indicated that an increase
in IFN-γ single and IFN-γ/TNF-α double-producing
CD4+ T cells led to an accelerated occurrence of PCV2-
specific IgG antibodies following PCV2 infection. This
raised the question if the IgG antibodies seen at 32 days
post infection (dpi) in four out six animals of the IN
group were also preceded by an increase of PCV2-specific
cytokine-producing CD4+ T cells. Therefore, PBMCs iso-
lated from the IN group were tested also 18 dpi and data
is displayed in a time course (Figure 5). Indeed, three of
the four animals with PCV2-specific IgG antibodies atllowing PCV2 infection. PBMCs isolated from PCV2 infected animals
n (dpi) were stimulated with PCV2-ORF2. CD4+ T cells were gated as
r charts indicate percentages of cytokine-producing CD4+ T cells from
ucing CD4+ T cells and filled bars illustrate percentages of IFN-γ/TNF-α
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IFN-γ single and IFN-γ/TNF-α double-producing CD4+
T cells at 18 dpi. IN5 and IN6 who lacked single and
double cytokine-producing T cells 18 dpi were only
positive for IgM by the end of the study and did not
perform a class switch to IgG.
Lastly, having observed the marked induction of IFN-γ/
TNF-α co-producing CD4+ T cells following PCV2 vac-
cination and also PCV2 infection, we compared the CD27
expression in PCV2-specific IFN-γ+TNF-α+CD4+ T cells
from VA animals at 24 dpv (day of experimental infection),Figure 6 Memory phenotype of IFN-γ/TNF-α co-producing CD4+ T cel
TNF-α production following PCV2-ORF2 restimulation. IFN-γ/TNF-α double
CD8α and CD27 expression. Representative data of animals VA6 (24 dpv), IN
in the scatter diagrams represent percentages of CD27− effector memory T
subpopulation of IFN-γ/TNF-α co-producing T cells. Data is shown for indiv
infected (VI) group. The investigated time points correspond to 24 dpv (chIN animals at the day of euthanasia and VI animals at both
time points (Figure 6). Regardless of the treatment group
and the time point, CD27+ central memory T cells (TCM)
were present in higher frequencies than CD27− effector
memory T cells (TEM) in the vast majority of samples.
Discussion
PCV2 continues to be a highly relevant pathogen for
modern swine production which needs to be controlled
by vaccination [2]. The role of the humoral immune res-
ponse after PCV2 vaccination has been extensively studiedls. A) CD4+ T cells were gated (not shown) and analysed for IFN-γ and
cytokine-producing CD4+ T cells were sub-gated and investigated for
3 (56 dpv) and VI6 (challenge and euthanasia) are shown. B) Symbols
cells (TEM) and CD27
+ central memory T cells (TCM) within the
idual animals of the vaccinated (VA), infected (IN) and vaccinated &
allenge) and 56 dpv (euthanasia).
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Based on a controlled PCV2 vaccination-infection experi-
ment, the present study puts a strong focus on the role of
CD4+ T cells and their potential role following vaccination
and/ or infection.
Clinical signs
Clinical manifestation of PCV2 infection varies and can
result in distinct diseases. Most pigs are subclinically in-
fected. In other cases lung disease, enteric disease, repro-
ductive failure or porcine dermatitis and nephropathy
syndrome (PDNS) may occur. PMWS is the economically
most important manifestation of PCV2 infection [3,4]. It
is generally accepted, that PCV2 alone is not sufficient to
induce PCVD. Coinfections with other viral or bacterial
pathogens are needed to provoke more severe clinical
symptoms [5]. Accordingly, we did not observe any signs
of PCVD after singular PCV2 infection in our animal
experiment.
PCV2 viral load in serum samples
Detection of PCV2 antigen within characteristic micro-
scopic lesions is one of the key requirements for PCVD
diagnosis [24,25]. In addition, determination of high viral
loads (> 104.7 PCV2 copies/mL) in serum samples by
qPCR is an indicator for PCVD [4]. Hence, we analysed
serum samples collected at regular intervals throughout
the vaccination-infection experiment for the amount of
PCV2 DNA. In our study, viremia occurred in the IN
group only. Interestingly, piglets vaccinated with the
PCV2 subunit vaccine seemed to be protected and did
not develop viremia after PCV2 inoculation (Figure 2).
This is in accordance with other studies: in field studies,
the same PCV2 subunit vaccine significantly reduced
PCV2 viral load and duration of viremia in sera of pigs
suffering from PMWS and porcine respiratory disease
complex (PRDC), respectively [26,27]. Under experimental
conditions, four commercially available PCV2 vaccines,
including the subunit vaccine used in our study, signifi-
cantly decreased PCV2 DNA in the blood after PCV2
challenge [28]. However, in all these studies viremia was
not completely prevented by PCV2 vaccination. Neverthe-
less, we assume that our experimental infection was suc-
cessful because similar levels of viremia were achieved
after singular PCV2 infection elsewhere [28].
Serology
Serum antibodies against PCV2 are wide spread in pig
populations all over the world [12,14]. However, the ana-
lysis of PCV2-specific antibody titres is challenging from
a technical perspective. Several studies revealed that vast
differences among laboratories and various ELISA test
systems exist [29,30]. Despite these issues, we decided to
use a qualitative ELISA capable of distinguishing IgMfrom IgG antibodies. This enabled us to differentiate be-
tween maternally derived and vaccine induced antibodies.
24 dpv PCV2-specific antibodies, which were considered
to be induced by vaccination, were detected in five out of
12 vaccinated piglets. After experimental infection, all in-
fected animals seroconverted independent of vaccination
status. Of note, seroconversion occurred earlier in VI pigs
than in IN pigs. These results are comparable to previous
data. Several recent studies described that pigs vaccinated
with PCV2 subunit vaccines showed a prompt serocon-
version and had increased antibody titres compared to
their non-vaccinated counterparts under experimental
conditions as well as after natural PCV2 infection [28,31].
Although all animals of the VI group had detectable
PCV2-specific IgG titres at the end of the study, for
some individuals this was not preceded by a clear IgM
response. However, although titres remained below the
cut-off value, in tendency also VI animals 3, 4, 5 and 6
showed an increase in OD-values for IgM from −4 dpv
to 24 dpv. In addition, it is conceivable that these ani-
mals with IgM titres below the cut-off had higher titres
before day 24 post vaccination. Nevertheless, antibodies
of the IgG isotype were predominant in samples of VI
pigs, whereas a mixture of IgM and IgG antibodies was
found in IN pigs (Figure 3). The early occurrence of IgG
antibodies is most probably a beneficial effect of the
vaccination which may be related to the presence of
vaccine-specific CD4+ T cells with a helper function
(see also below).
Cytokine production of CD4+ T cells and phenotype of
cytokine-producing cells
It is likely that a sufficient protection against PCV2 in-
fection is achieved by a response of both the humoral
and the cellular immune system following vaccination.
So far, little is known about the cellular immune response
and knowledge on the development of antigen-specific T
memory cells after PCV2 vaccination is sparse. Therefore,
a detailed examination of vaccine induced antigen-specific
CD4+ T cells and their IFN-γ/TNF-α production was the
main focus of our study. To evaluate the memory pheno-
type of cytokine-producing cells, we further analysed the
expression of CD8α and CD27. As mentioned above,
CD8α can be found on activated, antigen experienced T
cells and memory T cells whereas naïve T helper cells
are considered CD8α negative [32]. Similar to humans
CD27 distinguishes between porcine central and ef-
fector memory T cells [33]. IFN-γ single and IFN-γ/
TNF-α co-producing CD4+ T cells induced after vaccin-
ation were mainly activated CD8α+ T cells. We detected
a homogenous distribution of CD27+ central memory T
cells (TCM) and CD27
− effector memory T cells (TEM)
within IFN-γ/TNF-α co-producing T cells in VA, IN and VI
pigs. Apparently, all memory phenotypes were addressed
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and Figure 6). With these findings we expand previous
knowledge that PCV2 vaccination elicits CD4+CD8α+
memory T cells [34].
So far, it is known that the development of IFN-γ se-
creting cells (SC) is a key event in cell-mediated PCV2
immunity [35]. A good example for that is the inverse
correlation of IFN-γ SC and numbers of PCV2 copies in
serum samples [28,36]. In the present study, we add-
itionally investigated the phenotype of the IFN-γ produ-
cing T cells by ICS after in vitro re-stimulation with
PCV2-ORF2. We detected a higher frequency of IFN-γ
single-producing CD4+ T cells in vaccinated animals
compared to their non-vaccinated counterparts at 24 dpv.
Similarly, the frequency of IFN-γ producing CD4+ T cells
increased in the IN group after experimental PCV2 in-
fection (Figure 4B, Figure 5). Obviously, this increase of
antigen-specific IFN-γ producing cells is a response to
vaccination and infection. Similar results were obtained
in studies investigating cell-mediated immune responses
against PCV2 based on determination of IFN-γ SC by
ELISpot assay. In accordance with our data, IFN-γ SC in
response to capsid protein were induced in vaccinated as
well as in vaccinated and challenged pigs [37]. Amounts
of PCV2-specific IFN-γ SC increased also in vaccinated
and naturally PCV2 infected pigs [38]. Unlike others,
we did not detect a further enhancement of cytokine-
producing cells after experimental infection in vacci-
nated and infected pigs [39].
Evidence exists that the magnitude of IFN-γ produc-
tion by CD4+ T cells alone is not always sufficient to
predict protection [40] and that multi-functional T cells,
which simultaneously produce IFN-γ, interleukin-2 (IL-2)
and TNF-α, are strongly correlated with protection [41].
Hence, in addition to IFN-γ, we investigated TNF-α ex-
pression by CD4+ T cells and consequently evaluated the
appearance of IFN-γ/TNF-α co-producing T cells. 24 dpv
we found elevated levels of IFN-γ+TNF-α+CD4+ T cells in
all vaccinated animals (VA, VI). The frequency of these
cells declined in the VA group towards the end of the
study (56 dpv). In the IN group we also observed these
double cytokine-producing T cells following PCV2 inocu-
lation. Similar to IFN-γ single-producing cells, no further
increase of co-producing T cells was observed in the VI
group after PCV2 challenge (Figure 4B). Nevertheless, it is
conceivable that the induction of PCV2-specific IFN-γ/
TNF-α co-producing CD4+ T cells by a non-replicative
agent, i.e. the ORF2 subunit vaccine, is sufficient to con-
trol a subsequent PCV2 infection. Another important
finding of this study is that the occurrence of cytokine-
producing CD4+ T cells 18 dpi was associated with a sub-
sequent isotype-switch from IgM to IgG in the IN group.
This phenomenon may be interpreted as a helper function
of CD4+ T cells for antibody production and antibodyclass switch and support the hypothesis that these dou-
ble cytokine-producing T cells play a role in protection
against PCV2.
In conclusion, our data shows that PCV2 vaccination
did not induce stable titres of PCV2-specific IgG anti-
bodies in all vaccinated animals. Nevertheless, the PCV2
subunit vaccine was highly efficacious and prevented
viremia in all vaccinated and infected pigs. Moreover,
the amount of IFN-γ producing CD4+ T cells increased
after PCV2 vaccination and/ or infection. Contrary to
PCV2-specific antibodies, antigen-specific IFN-γ+TNF-
α+CD4+ T cells were induced in all vaccinated pigs. The
appearance of these cells seems to be linked to a switch
from IgM to IgG indicating their relevance for pro-
tection after PCV2 infection. Therefore, IFN-γ/TNF-α
co-producing T cells might represent a new correlate of
an immune reaction after PCV2 vaccination and their
existence after vaccination might correlate with protec-
tion. This finding needs further investigation.
Additional files
Additional file 1: Mean cytokine production of PCV2-ORF2 specific
CD4+ T cells. Stacked bar charts indicate mean percentages of cytokine-
producing CD4+ T cells of the respective groups (CO = control, VA =
vaccinated, IN = infected, VI = vaccinated & infected) at the investigated
time points prior to challenge (C, 24 days post vaccination) and at the
day of euthanasia (E, 56 days post vaccination). Hatched bars represent
percentages of IFN-γ single-producing CD4+ T cells and filled bars illustrate
percentages of IFN-γ/TNF-α co-producing CD4+ T cells. Minuscules indicate
significant differences (p < 0.05) between treatment groups and investigated
time points, respectively. For IFN-γ single-producing CD4+ T cells significant
differences were detected between CO and IN at the end of the study
(E) (a:b p = 0.035) and within the VA group between 24 dpv (C) and 56 dpv
(E) (c:d p = 0.004). For IFN-γ/TNF-α co-producing CD4+ T cells differences
were significant on day 24 post vaccination between CO and VA
(e:f p = 0.044), CO and VI (e:g p = 0.006) and IN and VI (g:h p = 0.011).
On study day 56 post vaccination differences were significant between
CO and VA, IN and VI, respectively (i:j p = 0.006). Within the IN group
more IFN-γ/TNF-α co-producing CD4+ T cells were detected after
experimental infection (h:j p = 0.046) and in both vaccinated groups
(VA and VI) frequency of double cytokine-producing cells declined
towards the end of the study (56 dpv) (f:j; g:j p = 0.028).
Additional file 2: Cytokine production of CD4+ T cells in the time
course before and after PCV2 vaccination. The frequency of PCV2-
ORF2-specific cytokine-producing CD4+ T cells in the time course before
and after vaccination for three animals of the vaccinated (VA, top panel)
and three animals of the vaccinated and infected group (VI, bottom
panel) was analysed. Contour plots display data from one representative
animal (VI1) before vaccination and 24 days post vaccination (dpv).
PBMCs were stimulated with PCV2-ORF2 and CD4+ T cells were gated as
described above. Stacked bar charts indicate percentages of cytokine-
producing CD4+ T cells before vaccination as well as 24 and 56 dpv from
individual animals. Hatched bars represent percentages of IFN-γ single-
producing CD4+ T cells and filled bars illustrate percentages of IFN-γ/
TNF-α co-producing CD4+ T cells within total CD4+ T cells.
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